Skip to main content

Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial

Cancer Chemotherapy and Pharmacology volume 52, pages 13–18 (2003)Cite this article

Abstract

Objective

To determine which hydration (saline, saline + mannitol, or saline + furosemide) is associated with least cisplatin nephrotoxicity.

Methods

We randomized 49 women who received cisplatin (75 mg/m2 every 3 weeks) into one of the three hydration arms. The 24-h creatinine clearance was measured before and on day 6 after cisplatin infusion. The patients of each arm received 2 l of saline hydration. In the saline + furosemide arm, 40 mg of furosemide was given after hydration. In the saline + mannitol arm, 50 g of mannitol was mixed with the cisplatin.

Results

For the first cycle of chemotherapy, 15 women were randomized to saline, 17 to saline + furosemide, and 17 to saline + mannitol. For each group, the creatinine clearances before cisplatin infusion were (means±SD, milliliters per minute) 84.5±26.8, 82.5±24.0 and 87.4±25.6, and after cisplatin infusion were 79.1±31.9, 68.7±21.5, and 56.4±22.9, respectively. The decreases in creatinine clearance were similar between the saline group and the saline + furosemide group (P=0.66), but different between the saline + mannitol group and the saline group (P=0.02) or the saline + furosemide group (P=0.02). As each woman received multiple courses of cisplatin, 15 who received saline contributed 41 paired datasets, 17 who received saline + furosemide contributed 49 paired datasets, and 17 who received saline + mannitol contributed 36 paired datasets showed similar patterns.

Conclusions

Hydration with saline or saline + furosemide appears to be associated with less cisplatin nephrotoxicity than saline + mannitol.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1.
Fig. 2.

References

  1. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao SY (1999) Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17:1339–1348

    CAS  PubMed  Google Scholar 

  2. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG (1999) Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340:1137–1143

    Article  CAS  PubMed  Google Scholar 

  3. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S (1999) Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340:1144–1153

    Article  CAS  PubMed  Google Scholar 

  4. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL, Gersell D (1999) Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340:1154–1161

    Article  CAS  PubMed  Google Scholar 

  5. Peters WA III, Liu PY, Barrett RJ, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr, Alberts DS (2000) Concurrent chemotherapy and pelvic radiation therapy as adjunctive therapy after radical surgery in high risk early stage carcinoma of the cervix. J Clin Oncol 18:1606–1613

    CAS  PubMed  Google Scholar 

  6. Ozols RF, Young RC (1985) High-dose cisplatin therapy in ovarian cancer. Semin Oncol 12:21–30

    CAS  Google Scholar 

  7. Cornelison TL, Reed E (1993) Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin (review). Gynecol Oncol 50:147–158

    Article  CAS  PubMed  Google Scholar 

  8. Daugaard G, Abildgaard U, Larsen S (1987) Functional and histopathological changes in dog kidneys after administration of cisplatin. Renal Physiol 10:54–64

    CAS  PubMed  Google Scholar 

  9. Clayton DA, Doda JN, Fiedberg ED (1974) The absence of a pyrimidine dimer repair mechanism in mammalian mitochondria. Proc Natl Acad Sci U S A 71:2777–2781

    CAS  PubMed  Google Scholar 

  10. Gordon JA, Gattone VH (1986) Mitochondrial alteration in cisplatin-induced acute renal failure. Am J Physiol 250:F991–998

    CAS  PubMed  Google Scholar 

  11. Tisher CA (1981) Anatomy of the kidney. In: Brenner Rectors (eds) The kidney. Saunders, Philadelphia, pp 28–35

  12. Hayes DM, Cvitkovic E, Goldberg RB, Scheiner E, Helson L, Krakoff IH (1977) High dose cis-platinum diammine chloride. Cancer 39:1372–1381

    CAS  PubMed  Google Scholar 

  13. Higby DJ, Wallace HJ Jr, Albert DJ, Holland JF (1974) Diaminodichloroplatinum: a phase-I study showing responses in testicular and other tumors. Cancer 33:1219–1225

    CAS  PubMed  Google Scholar 

  14. Al-Sarraf M, Fletcher W, Oishi N (1982) Cisplatin hydration with and without mannitol diuresis in refractory disseminated malignant melanoma: a Southwest Oncology Group study. Cancer Treat Rep 66:31–35

    CAS  PubMed  Google Scholar 

  15. Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF (1977) Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39:1357–1361

    CAS  PubMed  Google Scholar 

  16. Ostrow O, Egorin MJ, Hahn D (1981) High dose cisplatin therapy using mannitol versus furosemide diuresis: comparative pharmacokinetics and toxicity. Cancer Treat Rep 65:73–78

    CAS  Google Scholar 

  17. Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssai PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44:164–172

    CAS  PubMed  Google Scholar 

  18. Sobrero A, Guglemi A, Aschele C, Rosso R (1990) Current strategies to reduce cisplatin toxicity. J Chemother 2:3–7

    CAS  PubMed  Google Scholar 

  19. Chary KK, Higby DJ, Henderson ES (1977) Phase I study of high-dose cis-dichlorodiammineplatinum(II) with forced diuresis. Cancer Treat Rep 61:367–370

    CAS  PubMed  Google Scholar 

  20. Lehane D, Winston A, Gray R, Daskal Y (1979) The effect of diuretic pretreatment on clinical, morphological, and ultrastructural cis-platinum induced nephrotoxicity. Int J Radiat Oncol Biol Phys 5:1393–1399

    CAS  PubMed  Google Scholar 

  21. Gehr M, Chopra S, Kaufman J, Chase D, Fjlamenbaum W (1981) The effect of furosemide on cis-diamminedichloroplatinum-induced acute renal failure. Kidney Int 19:201–204

    Google Scholar 

  22. Ward JM, Grabin ME, LeRoy AF, Young DM (1977) Modification of the renal toxicity of cis-diamminedichloroplatinum (II) with furosemide in male F344 rats. Cancer Treat Rep 61:375–379

    CAS  PubMed  Google Scholar 

  23. Fisher DS, Knobf MT, Durivage HJ (1989) The cancer chemotherapy handbook, 4th edn. Mosby Yearbook, St. Louis

  24. Anad AJ, Bashey B (1993) Newer insights into cisplatin nephrotoxicity. Ann Pharmacother 27:1519–1525

    PubMed  Google Scholar 

  25. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, Surwit EA, Malvlya VK, Nahhas WA, Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III & IV ovarian cancer. J Clin Oncol 10:706–717

    CAS  PubMed  Google Scholar 

  26. Kemp G, Rose P, Lurain J, Berman M, Manetta A, Roullet B, Homesley H, Belpomme D, Glick J (1996) Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J Clin Oncol 14:2101–2112

    CAS  PubMed  Google Scholar 

  27. Levey AS, Perrone RD, Madias NE (1988) Serum creatinine and renal function. Annu Rev Med 39:465–490

    Article  CAS  PubMed  Google Scholar 

  28. Daugaard G, Rossing N, Rorth M (1988) Effects of high dose cisplatin on glomerular function in the human kidney. Cancer Chemother Pharmacol 21:163–167

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We wish to thank Robert Safirstein MD for his assistance in designing the study and James J. Grady DrPH for statistical assistance.

Author information

Affiliations

  1. University of Tennessee Cancer Institute, 1331 Union Ave., Suite 800, Memphis, TN 38104, USA

    Joseph T. Santoso

  2. Clinical Science Building Room 316, University of Texas Medical Branch, 301 University Blvd, Galveston, TX 77555, USA

    Joseph A. Lucci III, Ilona Schafer & Edward V. Hannigan

  3. Division of Gynecologic Oncology, Southwestern Medical Center, University of Texas, 5323 Harry Hines Blvd, Dallas, TX 75390, USA

    Robert L. Coleman

Authors
  1. Joseph T. Santoso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph A. Lucci III
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert L. Coleman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ilona Schafer
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Edward V. Hannigan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph T. Santoso.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Santoso, J.T., Lucci, J.A., Coleman, R.L. et al. Saline, mannitol, and furosemide hydration in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 52, 13–18 (2003). https://doi.org/10.1007/s00280-003-0620-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-003-0620-1

Keywords

  • Hydration
  • Cisplatin nephrotoxicity
  • Mannitol
  • Furosemide